Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 8, Issue 2, Pages e000698
Publisher
BMJ
Online
2020-08-06
DOI
10.1136/jitc-2020-000698
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PD-1 Ligand Expression in Epithelial Thyroid Cancers: Potential Clinical Implications
- (2019) Salvatore Ulisse et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
- (2019) Paolo Antonio Ascierto et al. NATURE MEDICINE
- Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
- (2019) Antoni Ribas et al. NATURE MEDICINE
- Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1
- (2019) Yujie Zhu et al. Molecular Therapy-Oncolytics
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
- (2018) Frederick Arce Vargas et al. CANCER CELL
- Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
- (2018) Heng Lin et al. JOURNAL OF CLINICAL INVESTIGATION
- PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
- (2018) Haidong Tang et al. JOURNAL OF CLINICAL INVESTIGATION
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
- (2018) Vivek Subbiah et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunological effects of BRAF+MEK inhibition
- (2018) Paolo A. Ascierto et al. OncoImmunology
- Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
- (2018) Priyanka C. Iyer et al. Journal for ImmunoTherapy of Cancer
- Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer
- (2018) Viswanath Gunda et al. BRITISH JOURNAL OF CANCER
- Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer
- (2018) Viswanath Gunda et al. INTERNATIONAL JOURNAL OF CANCER
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation
- (2018) Praveen K. Bommareddy et al. Science Translational Medicine
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer
- (2017) Revathi Kollipara et al. ONCOLOGIST
- Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer
- (2016) Adel Samson et al. GUT
- BRAF Inhibition inBRAFV600E-Positive Anaplastic Thyroid Carcinoma
- (2016) Annette M. Lim et al. Journal of the National Comprehensive Cancer Network
- Sustained Response to Vemurafenib in aBRAFV600E-Mutated Anaplastic Thyroid Carcinoma Patient
- (2016) Gerald W. Prager et al. THYROID
- BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients
- (2016) Langping Jin et al. Oncotarget
- Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer
- (2016) Eran Brauner et al. Oncotarget
- Treatment of Human Thyroid Carcinoma Cells with the G47delta Oncolytic Herpes Simplex Virus
- (2015) Jia-Ni Wang et al. Asian Pacific Journal of Cancer Prevention
- Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
- (2015) Maria Romina Girotti et al. CANCER CELL
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- (2015) Matthew E. Ritchie et al. NUCLEIC ACIDS RESEARCH
- Association of oncolytic adenoviruses with chemotherapies: An overview and future directions
- (2014) Christian Bressy et al. BIOCHEMICAL PHARMACOLOGY
- Human Anaplastic Thyroid Carcinoma Cells Are Sensitive to NK Cell-Mediated Lysis via ULBP2/5/6 and Chemoattract NK Cells
- (2014) E. Wennerberg et al. CLINICAL CANCER RESEARCH
- p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer
- (2014) D. G. McFadden et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer
- (2013) Mingzhao Xing et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- BRAF V600E Inhibition in Anaplastic Thyroid Cancer
- (2013) Michael H. Rosove et al. NEW ENGLAND JOURNAL OF MEDICINE
- Capacity of wild-type and chemokine-armed parvovirus H-1PV for inhibiting neo-angiogenesis
- (2013) Muriel Lavie et al. VIROLOGY
- NanoStringNorm: an extensible R package for the pre-processing of NanoString mRNA and miRNA data
- (2012) Daryl Waggott et al. BIOINFORMATICS
- BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
- (2012) C. Liu et al. CLINICAL CANCER RESEARCH
- BRAF inhibition improves tumor recognition by the immune system
- (2012) Marco Donia et al. OncoImmunology
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- BRAFV600E Mutation is Associated with Tumor Aggressiveness in Papillary Thyroid Cancer
- (2011) Su-jin Kim et al. WORLD JOURNAL OF SURGERY
- Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck
- (2010) K. J. Harrington et al. CLINICAL CANCER RESEARCH
- Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice
- (2009) Nathalie Dhomen et al. CANCER CELL
- Synergy of a Herpes Oncolytic Virus and Paclitaxel for Anaplastic Thyroid Cancer
- (2008) S.-F. Lin et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started